| SARWAR ONCOLOGY LIMITED |
| Registered number: |
09591401 |
| Balance Sheet |
| as at 31 May 2025 |
|
| Notes |
|
|
2025 |
|
|
2024 |
|
|
|
|
£ |
|
|
£ |
| FIXED ASSETS |
| Tangible assets |
3 |
|
|
1,141 |
|
|
273 |
|
| CURRENT ASSETS |
| Debtors |
4 |
|
29,826 |
|
|
31,872 |
| Cash at bank and in hand |
|
|
331,393 |
|
|
277,581 |
|
|
|
361,219 |
|
|
309,453 |
| CREDITORS: amounts falling due within one year |
5 |
|
(15,597) |
|
|
(15,234) |
|
| NET CURRENT ASSETS |
|
|
|
345,622 |
|
|
294,219 |
|
| TOTAL ASSETS LESS CURRENT LIABILITIES |
|
|
|
346,763 |
|
|
294,492 |
|
| Provisions for liabilities |
|
|
|
(216) |
|
|
(51) |
|
| NET ASSETS |
|
|
|
£ 346,547 |
|
|
£ 294,441 |
|
|
|
|
|
|
|
|
| CAPITAL AND RESERVES |
| Called up share capital |
|
|
|
1 |
|
|
1 |
| Profit and loss account |
|
|
|
346,546 |
|
|
294,440 |
|
| SHAREHOLDER'S FUNDS |
|
|
|
£ 346,547 |
|
|
£ 294,441 |
|
|
|
|
|
|
|
|
| The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
| The member has not required the company to obtain an audit in accordance with section 476 of the Act. |
| The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
| The accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account is not delivered to Companies House. |
|
|
| Dr M N Sarwar |
| Director |
| Approved by the board on 18 May 2026 |
|
| SARWAR ONCOLOGY LIMITED |
| Notes to the Accounts |
| for the year ended 31 May 2025 |
|
| 1 |
ACCOUNTING POLICIES |
|
|
Basis of preparation |
|
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard). |
|
|
Turnover |
|
Turnover is measured at the fair value of the consideration receivable, net of discounts and value added taxes. Turnover from the sale of any goods is recognised when goods are delivered and legal title has passed. |
|
|
Tangible fixed assets |
|
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows: |
|
|
Office equipment |
25% p.a. on a reducing balance basis |
|
|
Deferred taxation |
|
Full provision is made for deferred taxation resulting from timing differences between the recognition of gains and losses in the accounts and their recognition for tax purposes. Deferred taxation is calculated on a non-discounted basis at the tax rates which are expected to apply in the periods when the timing differences are expected to reverse. |
|
|
| 2 |
EMPLOYEES |
2025 |
|
2024 |
|
|
|
|
|
|
Number |
|
Number |
|
|
Average number of persons employed by the company |
|
(excluding directors with no specific service contract) |
- |
|
- |
|
|
|
|
|
|
|
|
|
|